Trials / Unknown
UnknownNCT02352077
NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair
Safety and Efficacy of NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Chinese Academy of Sciences · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of NeuroRegen scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) in patients with chronic spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NeuroRegen scaffold with BMMCs or MSCs transplantation | Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2015-02-02
- Last updated
- 2020-12-23
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02352077. Inclusion in this directory is not an endorsement.